Nymox Reports Positive Results For Prostate Cancer Trial With NX-1207

(RTTNews) - Nymox Pharmaceutical Corp. (NYMX) Tuesday said it recorded positive results for the clinical trial of investigative drug NX-1207 for the treatment of low grade localized prostate cancer. The study found that NX-1207 treated patients required less radiation and surgery compared with the control group.

The Phase 2 U.S. Trial, using NX03-0040, enrolled 146 patients and either randomized to one of two doses of NX-1207 2.5 mg or 15 mg or to no treatment. The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies were then performed on all patients. After up to 22 months, patients treated with NX-1207 single-injection showed an 85 percent reduction compared with control group.